DPP4 and type 2 diabetes mellitus: Development of small molecules-based approaches emerging to treat Type-II diabetes, like incorporating 2(S)-cyanopyrrolidine scaffold into a molecule, has been used often & has become a key intermediate for the synthesis of DPP-4 inhibitors [11].